Phase 0 clinical trials in oncology: A paradigm shift for early drug development?

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 4, 2009, Pages 703-709

  Takimoto, Chris H ^a,b  

^a South Texas Accelerated Research Therapeutics   (United States)

^b Mail Stop RA 2 2 ^*  (United States)

Author keywords

Drug development; Exploratory IND; Phase 0

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; DIAZEPAM; ERYTHROMYCIN; MIDAZOLAM; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; UNCLASSIFIED DRUG; ZK 253;

ARTICLE; CANCER PATIENT; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL ETHICS; NATIONAL HEALTH ORGANIZATION; ONCOLOGY; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; UNITED STATES; UNITED STATES DEPARTMENT OF AGRICULTURE;

EID: 58849138367     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0789-4     Document Type: Article

References (17)

1. European Medicines Agency (2004) Position paper on non-clinical safety studies to support clinical trials with a single microdose. European Medicines Agency. ( http://www.emea.europa.eu/pdfs/human/swp/259902en.pdf )
2. Food and Drug Administration (2004) Innovation or stagnation: challenges and opportunity on the critical path to new medical products. US Department of Health and Human Services. ( http://www.fda.gov/oc/initiatives/criticalpath/ whitepaper.html )
3. Food and Drug Administration (2006) Guidance for industry, investigators, and reviewers: Exploratory IND studies. US Department of Health and Human Services. ( http://www.fda.gov/CDER/guidance/7086fnl.htm )
4. Food and Drug Administration (2006) Guidance for Industry: INDs-approaches to complying with CGMP during Phase 1 (draft guidance). US Department of Health and Human Services. ( http://www.fda.gov/CDER/guidance/ 6164dft.htm )
5. M Gutierrez S Kummar Y Horneffer L Juwara A Chen G Melillo O Pickeral J Tomaszewski AJ Murgo JH Doroshow NPW Group 2007 Recruitment experience in a Phase 0 trial of ABT-888, an inhibitor of poly (ADP-ribose) polymerse (PARP), in patients (pts) with advanced malignancies J Clin Oncol 25 14111
6. TP Hill 2007 Phase 0 trials: are they ethically challenged? Clin Cancer Res 13 783 784
7. R Kinders M Hollingshead R Parchment S Khin G Kaur L Phillips J Tomaszewski J Doroshow NPW Group 2007 Preclinical modeling of a Phase 0 clinical trial protocol J Clin Oncol 25 14058
8. S Kummar R Kinders M Gutierrez L Rubinstein R Parchment L Phillips J Low A Murgo E Tomaszewski J Doroshow NCI Phase 0 Working Group 2007 Inhibition of poly (ADP-ribose) polymerase (PARP) by ABT-888 in patients with advanced malignancies: results of a Phase 0 trial J Clin Oncol 25 3518
9. S Kummar R Kinders L Rubinstein RE Parchment AJ Murgo J Collins O Pickeral J Low SM Steinberg M Gutierrez S Yang L Helman R Wiltrout JE Tomaszewski JH Doroshow 2007 Compressing drug development timelines in oncology using phase '0' trials Nat Rev Cancer 7 131 139
10. G Lappin RC Garner 2003 Big physics, small doses: the use of AMS and PET in human microdosing of development drugs Nat Rev Drug Discov 2 233 240
11. G Lappin W Kuhnz R Jochemsen J Kneer A Chaudhary B Oosterhuis WJ Drijfhout M Rowland RC Garner 2006 Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs Clin Pharmacol Ther 80 203 215
12. R Parchment R Kinders M Hollingshead J Dancy J Tomaszewski J Doroshow NPW Group 2007 Technical criteria of "clinical readiness' to qualify validated pharmacodynamic (PD) assays for clincial trial use J Clin Oncol 25 14068
13. JW Park RS Kerbel GJ Kelloff JC Barrett BA Chabner DR Parkinson J Peck RW Ruddon CC Sigman DJ Slamon 2004 Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development Clin Cancer Res 10 3885 3896
14. K Ratnam JA Low 2007 Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology Clin Cancer Res 13 1383 1388
15. L Rubinstein S Steinberg S Kummar J Low RE Parchment R Kinders M Gutierrez AJ Murgo JH Doroshow J Tomaszewski NPW Group 2007 Statistical considerations for a phase 0 trial J Clin Oncol 25 14038
16. R Twombly 2006 Slow start to Phase 0 as researchers debate value J Natl Cancer Inst 98 804 806
17. RL Woosley J Cossman 2007 Drug development and the FDA's critical path initiative Clin Pharmacol Ther 81 129 133